Jeffrey Rosenfeld, MD
Neuromuscular Medicine · Fresno, CANPI 1811912348
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (47.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Argenx US, Inc. at 49.3% of the total. Among neuromuscular medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 355 payments — averaging $1016.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$178K
- Tanabe Pharma America, Inc.$47K
- Amylyx Pharmaceuticals, Inc.$36K
- Strongbridge US Inc.$30K
- Catalyst Pharmaceuticals, Inc.$28K
- AstraZeneca$13K
- plus $28K from 11 others
Across 101 payments — averaging $10,925 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Tanabe Pharma America, Inc.$599K
- AstraZeneca$256K
- Novartis$108K
- Argenx US, Inc.$69K
- Mallinckrodt Enterprises LLC$23K
- Mitsubishi Tanabe Pharma Development America, Inc.$21K
- plus $28K from 5 others
What the payments were for
- Consulting fees$173,02148%
- Speaking & faculty fees$153,75543%
- Travel & lodging$27,6298%
- Food & beverage$6,2812%
- Education$2400%
- Gifts$660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 170 | $178,005 |
| Tanabe Pharma America, Inc. | 54 | $47,445 |
| Amylyx Pharmaceuticals, Inc. | 31 | $36,081 |
| Strongbridge US Inc. | 33 | $29,908 |
| Catalyst Pharmaceuticals, Inc. | 16 | $28,169 |
| AstraZeneca | 10 | $12,913 |
| UCB, Inc. | 13 | $9,887 |
| Genentech USA, Inc. | 9 | $9,005 |
| Biogen | 8 | $5,490 |
| CSL Behring | 1 | $1,950 |
| Amgen | 2 | $1,850 |
| PTC Therapeutics, Inc. | 1 | $79 |
| Saol Therapeutics Inc. | 2 | $66 |
| Genentech, Inc. | 1 | $63 |
| Baxter Healthcare | 2 | $57 |
| Grifols USA, LLC | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$360,992 in reported general payments places this provider in the 90th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 166 | $2,319,034 |
| EvrysdiRisdiplam | 73 | $1,926,935 |
| VyvgartEfgartigimod Alfa-Fcab | 23 | $1,665,561 |
| FirdapseAmifampridine Phosphate | 12 | $723,588 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 47 | $589,777 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 15 | $187,220 |
| NuedextaDextromethorphan Hbr/Quinidine | 27 | $62,196 |
| Riluzole | 81 | $23,321 |
| Pyridostigmine Bromide ErPyridostigmine Bromide | 15 | $4,133 |
| Pyridostigmine Bromide | 36 | $1,994 |
| Dantrolene Sodium | 18 | $1,480 |
| Baclofen | 38 | $1,388 |
| Tizanidine Hcl | 30 | $767 |
| Mycophenolate Mofetil | 12 | $677 |
| Gabapentin | 31 | $596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Genentech USA, Inc.Evrysdi | $9,005 | $1,926,93573 claims |
| Argenx US, Inc.Vyvgart | $178,005 | $1,665,56123 claims |
| Catalyst Pharmaceuticals, Inc.Firdapse | $28,169 | $723,58812 claims |
| Grifols USA, LLCGamunex-C | $23 | $589,77747 claims |
| Amylyx Pharmaceuticals, Inc.Relyvrio | $36,081 | $187,22015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Fresno
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- John DayStanford$294K
- Marwa KaiseyWest Hollywood$264K
- Namita GoyalOrange$174K
- Ana Tesi RochaPalo Alto$154K
- Jay HanOrange$126K
- Steven CramerLos Angeles$112K
- Khalid AlrasheedOrange$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.